Last reviewed · How we verify

NCT04745806

Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds

Terminated NA Last updated 15 November 2024
What this trial tests

NA trial testing ActiGraft in Wounds in 6 participants. Terminated before completion.

Timeline
1 March 2021
Primary endpoint
1 January 2023
1 January 2023

Quick facts

Lead sponsorRedDress Ltd.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment6
Start date1 March 2021
Primary completion1 January 2023
Estimated completion1 January 2023
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

RedDress Ltd.

Who can join

18 and older, any sex, with Wounds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer benefit from the study treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ActiGraft

Trials testing the same drug.

Other recruiting trials for Wounds

Currently open trials in the same condition.

Other RedDress Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04745806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing